Mpox Remains a Global Health Risk

The World Health Organization (WHO) has published its 60th situation report on the multi-country mpox outbreak. Since May 2022, when the mpox outbreak was first recorded, the WHO's report offers insights into the global epidemiological situation and includes updated data on this severe disease.

As of December 8, 2025, the WHO stated that all clades of the monkeypox virus (MPXV) continue to circulate. When mpox outbreaks are not rapidly contained, and human-to-human transmission is not interrupted, there is a risk of sustained community transmission.

For example, in October 2025, 44 countries across all WHO regions reported 2,501 new confirmed mpox cases, including 12 related deaths, for a case fatality ratio of 0.5%. About 75% of these cases were reported in the African Region. 

Outside Africa, local transmission of clade Ib MPXV has been occurring in Italy, the Netherlands, Portugal and Spain, the United States of America, and Malaysia.

New imported mpox cases due to clade Ib MPXV have been detected among travellers in Belgium, Germany, Greece, and the United Kingdom of Great Britain and Northern Ireland.

According to the U.S. CDC, mpox is a vaccine-preventable disease and is recommended for those at risk.

Getting both recommended JYNNEOS doses provides the best protection against monkeypox.

The CDC says that whether or not you've been vaccinated, you can continue to reduce your risk of getting monkeypox.